Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation

OBJECTIVES: This study aims to inhibit antiphospholipid syndrome (APS) serum derived IgA anti-beta-2-glycoprotein I (aβ2GPI) binding using Domain I (DI). METHODS: Serum from 13 APS patients was tested for IgA aβ2GPI and Anti-Domain I. Whole IgA was purified by peptide M affinity chromatography from...

Descripción completa

Detalles Bibliográficos
Autores principales: Albay, A, Artim-Esen, B, Pericleous, C, Wincup, C, Giles, I, Rahman, A, McDonnell, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Concise Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567316/
https://www.ncbi.nlm.nih.gov/pubmed/31126213
http://dx.doi.org/10.1177/0961203319851571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567316/
https://www.ncbi.nlm.nih.gov/pubmed/31126213
http://dx.doi.org/10.1177/0961203319851571

Ejemplares similares